Xtandi drug combo reduces risk of prostate cancer metastasis and death.
TL;DR
Pfizer and Astellas have reported that their drug Xtandi, in combination with leuprolide, reduces the risk of metastasis and death in prostate cancer by 58%. The Phase III EMBARK trial tested Xtandi plus leuprolide and Xtandi as a monotherapy against placebo plus leuprolide in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. The companies believe that the data shows the potential for Xtandi to be added to the standard of care if a label expansion is approved.
Topics:businesshealthcare#astellas#clinical-trial#drug-combination#healthcare#pfizer#prostate-cancer
- Pfizer, Astellas say Xtandi drug combo reduces risk of metastasis, death in prostate cancer by 58% Endpoints News
- Pfizer, Astellas detail Xtandi win in earlier prostate cancer FiercePharma
- Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer Medpage Today
- Pfizer, Astellas Xtandi combo cuts risk of death by 58% in prostate cancer patients Seeking Alpha
- Enzalutamide plus leuprolide reduces risk of metastasis by nearly 60% in nonmetastatic HSPC Urology Times
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News